Transferrin receptor‐independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression

D Trinder, O Zak, P Aisen – 1 June 1996 – The hepatic uptake of transferrin‐bound iron by a nontransferrin receptor (NTR)‐mediated process was investigated using the human hepatoma cell line HuH7. Because HuH7 cells also acquire iron from transferrin by a receptor (TR)‐mediated process, TR expression was inhibited by transfecting the cells with a plasmid containing human TR complementary DNA in antisense orientation relative to a human cytomegalovirus promoter/enhancer element.

FK506 inhibits human lymphocyte migration and the production of lymphocyte chemotactic factors in liver allograft recipients

D H Adams, Q Liu – 1 June 1996 – The macroglide immunosuppressant FK506 is effective at preventing and reversing hepatic allograft rejection. The establishment of graft rejection is dependent upon an influx of lymphocytes from the circulation into the graft in response to locally secreted chemotactic factors. Thus, inhibition of lymphocyte migration might be an additional mode of action of FK506 that could block lymphocyte recruitment to rejecting liver allografts.

Fulminant hepatitis in a tropical population: Clinical course, cause, and early predictors of outcome

S K Acharya, S Dasarathy, T L Kumer, S Sushma, K S Prasanna, A Tandon, V Sreenivas, S Nijhawan, S K Panda, S K Nanda, M Irshad, Y K Joshi, S Duttagupta, R K Tandon, B N Tandon – 1 June 1996 – The profiles of patients with fulminant hepatic failure (FHF) from developing countries have not been reported earlier. The current study was conducted prospectively, at a single tertiary care center in India, to document the demographic and clinical characteristics, natural course, and causative profile of patients with FHF as well as to define simple prognostic markers in these patients.

Liver function in early Lyme disease

H W Horowitz, B Dworkin, G Forseter, R B Nadelman, C Connolly, B B Luciano, J Nowakowski, T A O'Brien, M Calmann, G P Wormser – 1 June 1996 – To evaluate the frequency, pattern, and severity of liver function test abnormalities in patients with Lyme disease associated with erythema migrans (EM), 115 individuals with no other identifiable cause for liver function test abnormalities who presented with EM between July 1990 and September 1993 were prospectively evaluated.

Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa

E Tanaka, K Kiyosawa, A Matsumoto, T Kashiwakuma, A Hasegawa, H Mori, O Yanagihara, Y Ohta – 1 June 1996 – The quantitation of hepatitis C virus (HCV) viremia can be helpful in the diagnosis, therapy, and monitoring of patients with chronic hepatitis C. A sensitive and quantitative fluorescence enzyme immunoassay (FEIA) has recently been developed for assaying HCV core protein in serum.

Modulation of basal hepatic glycogenolysis by nitric oxide

M Borgs, M Bollen, S Keppens, S H Yap, W Stalmans, F Vanstapel – 1 June 1996 – We perfused livers from fed rats with a balanced salt solution containing 1 mmol/L glucose. Under these conditions a low steady rate of glycogenolysis was observed (approximately 1.7 μmol glucose equivalents/g/min; 20% of the maximal glycogenolytic activity). Nitric oxide (NO) transiently stimulated hepatic glucose production. A maximal response (on average doubling basal glucose output) was observed with 34 μmol/L NO. The same concentration of nitrite (NO2‐) was ineffective.

Cloning of variable regions of an antibody that reacts with the soluble fraction of human liver cells and its possible value in chronic liver disease

H Saito, S Tada, H Ebinuma, K Atsukawa, T Masuda, Y Inagaki, K Tsuchimoto, T Morizane, H Ishii – 1 June 1996 – A gene encoding the variable regions of the heavy and light chains of a mouse monoclonal antibody designated H2, which specifically reacts with human liver cells, was cloned into a phagemid vector. The clone of the variable region was designed to be expressed as a separate protein, the structure of which is the same as that of the mouse antibody.

Features of autoimmune hepatitis in primary sclerosing cholangitis: An evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis

K M Boberg, O Fausa, T Haaland, E Holter, O J Mellbye, A Spurkland, E Schrumpf – 1 June 1996 – Overlapping features between primary sclerosing cholangitis (PSC and autoimmune hepatitis (AIH) have previously been noted. To assess systematically similarities between these disorders, we have evaluated 114 PSC patients (36 women; 78 men), all confirmed by endoscopic retrograde cholangiography (ERC), according to a scoring system proposed by The International Autoimmune Hepatitis Group for the diagnosis of AIH.

The long‐term pathological evolution of chronic hepatitis C

M Yano, H Kumada, M Kage, K Ikeda, K Shimamatsu, O Inoue, E Hashimoto, J H Lefkowitch, J Ludwig, K Okuda – 1 June 1996 – Most patients infected with hepatitis C virus (HCV) develop chronic hepatitis. Unfortunately, the pathological evolution of this disease over time is not completely understood. We studied 70 HCV‐positive patients, from whom 2 to 10 liver biopsy specimens (mean, 3.9) had been obtained during an interval of 1 to 26 years (mean, 8.8 years).

Biliary atresia: Current concepts and research directions. Summary of a symposium

W F Balistreri, R Grand, J H Hoofnagle, F J Suchy, F C Ryckman, D H Perlmutter, R J Sokol – 1 June 1996 – Biliary atresia (BA) is the end result of a destructive, inflammatory process that affects intra‐ and extrahepatic bile ducts, leading to fibrosis and obliteration of the biliary tract with the development of biliary cirrhosis. It is the commonest cause of chronic cholestasis in infants and children, and therefore is the most frequent indication for liver transplantation in this age group. The disease occurs worldwide, affecting an estimated 1 in 8,000 to 12,000 live births.

Subscribe to